• 107328  Infos

Semicarbazide-cadmium therapy

    FIELD: Medicine OncologyPat №2071767 RussiaSUBSTANCE: Method involves the use of the following preparations: semicarbazide hydrochloride urea cadmium halides at mass number 113 Additionally stable isotopes of gadolinium can be used in part its oxides at mass number 155-157 and addional drugs
    The first experimental study in humans were conducted in 1957-1962 in Russia as an open pilot trials: Cancer semicarbazide-cadmium therapy and experimental burn treatment( RESULTS OF THE USE OF SEMICARBAZIDE-CADMIUM THERAPY IN PATIENTS WITH INCURABLE MALIGNANT NEOPLASMS Vopr Onkol 1963;18:92-104 (US National Library of Medicine) "EXPERIENCE IN THE USE OF SEMICARBAZIDE-CADMIUM THERAPY IN PATIENTS SUFFERING FROM MALIGNANT NEOPLASMS IN THE INCURABLE PERIOD" Volokhonskaya ML ; Voronko ND ; Vysheslavtsev SI ; Yaroshevskii FYu Energy Citations Database) This “proof of principle” (1963) identifies semicarbazide as a potential drug for humans
    Clinical use of semicarbazide gives the evidence that an inflammatory reaction can be reduced by blocking the enzymatic activity of the Semicarbazide-sensitive amine oxidase (SSAO)The SSAO activity was found significantly increased in blood and tissues in some pathological conditions The enzyme activity has been reported to be elevated in diabetes and cancerThe mean specific activity of SSAO was significantly elevated in the group of patients having prostate cancer with skeletal metastases Semicarbazide ( and SSAO blockers ) can reduce inflammatory response can protect against the progressive vascular complications caused by oxidative stress It also can reduce pain (EUROMEDICAINTERNATIONALER MEDIZINISCHER KONGRESS HANNOVER 2007 GERMANY)
    The SSAO-inhibitors also appears able to protect endothelial cells against toxic effects of free radicals Semicarbazides are promising drugs for cancer therapy: United States Patent 6849631 "Semicarbazides and their uses" : This invention also provides a novel method of treating cancer or other proliferative diseases by administering a therapeutically effective amount of one of these compounds or a pharmaceutically acceptable salt form thereof)